Investors
Medipattern was founded in 1999 and began trading on the TSX Venture Exchange on May 6, 2005 under the symbol ‘MKI’. MKI, or Medipattern Knowledge-based Imaging, is the supporting principle of the company’s proprietary Cadenza™ Technology Suite.
Medipattern creates value for its shareholders through the development and commercialization of proprietary software solutions stemming from its Cadenza Technology Suite. Medipattern’s value proposition is two-fold:
- Streamline workflow to save time while enabling more detailed communication to increase medical practice effectiveness
- Provide a “second opinion” for advanced decision support through highlighting and identifying lesion characteristics and further training for physicians
The global women’s health market is valued at more than $20 billion by independent industry analyst Frost & Sullivan. A leading solution provider to that market, Medipattern derives its primary source of revenue from globally recognized resellers, such as GE Healthcare and Confirma. Medipattern’s highly experienced management team and respected advisory team help further ensure the company’s solid footing and continued high growth in this sector.
B-CAD is the first FDA-cleared software used for the detection and characterization of lesions found in breast ultrasound images. More recently, B-CAD became the first breast ultrasound CAD to receive SFDA clearance in the People’s Republic of China. In addition, Medipattern has leveraged the Cadenza platform to create a morphology tool for breast magnetic resonance imaging (MRI), making Medipattern the first company to develop multi-modality imaging technology spanning both ultrasound and MRI.
Medipattern’s principal offices are located at 3080 Yonge Street, Suite 4070, Toronto, Ontario, Canada, M4N 3N1.
Analysts
| Jon Hykawy | Research Capital |
| Douglas Loe | Versant Partners |
| Steven Gold | Clarus Securities |
| Husein Kirefu | M Partners |